Siamak Daneshmand, MD, explores genitourinary cancer updates presented at ESMO 2023.
November 27th 2023EP. 1: Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers
Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.
November 27th 2023EP. 2: Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023
An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.
November 27th 2023EP. 3: Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.
December 11th 2023EP. 4: ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
December 11th 2023EP. 5: Key Highlights from EV-302 Study at ESMO 2023
Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.
December 11th 2023EP. 6: LITESPARK-003 Trial Insights: Updates from ESMO 2023
An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).
December 11th 2023EP. 7: Future Opportunities in Genitourinary Cancers
Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.
